Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention
NCT02114528Phase 4Terminated
- Sponsor
- University of Ottawa Heart Institute
- Start
- Oct 2014
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ventricular tachycardia (VT) and ventricular arrhythmia (VA) (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Appropriate ICD therapy at 30 days. Started Oct 2014; status: terminated.
02
Conditions
ventricular tachycardia (VT)ventricular arrhythmia (VA)
Beyond the preview
Go deeper on NCT02114528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114528.